Bringing the technology together

It's not yet enough to declare a trend, but last week's deal between DNX Corp. and Baxter Healthcare Corp. is the third or fourth this year in which a lead company has gathered under one roof disparate pieces of technology in a related disease area, to form a coherent whole.

Nextran, the partnership formed between DNXX and Baxter, combines the organ transplantation programs from both companies, as well as technology previously licensed by Baxter from Cantab Pharmaceuticals plc (CNTBY) and SangStat Medical Corp. (SANG). (See What They Did.)...